---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

FORM 8-K

 

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2006

 

---

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

 

---

 

Delaware		1-32302		41-1350192
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

707 Eagleview Boulevard, Suite 414 Exton, PA		19341
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone, including area code: (610) 458-6200

Not applicable.

(Former name and former address, if changed since last report)

 

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2006, Antares Pharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first fiscal quarter ended March 31, 2006.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

99.1		–		Press Release dated May 15, 2006.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		ANTARES PHARMA, INC.
Date: May 19, 2006		By:		/s/ ROBERT F. APPLE
		Name:		Robert F. Apple
		Title:		Senior Vice President and Chief Financial Officer

---

EXHIBIT INDEX

 

Exhibit Number		Document
99.1		Press Release dated May 15, 2006.